Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arbaclofen Placarbil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 3/20 | 0.47 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 4/20 | 0.43 |
| ▸ | FNTB | P49356 | 4/20 | 0.43 |
| ▸ | PTGFR | P43088 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbaclofen Placarbil SCHEMBL2472988 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL638204 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL351833 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL3375708 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL14692761 | 0.99 | GABBR2 (0.46) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL14689524 | 0.99 | GABBR2 (0.46) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| Arbaclofen Placarbil SCHEMBL14689601 | 0.99 | GABBR2 (0.46) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| SCHEMBL12130896 | 0.91 | MAPT (0.39) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| SCHEMBL13101899 | 0.91 | MAPT (0.40) | GABBR2GABBR1LMNACYP2C9KMT2A | |
| SCHEMBL2230566 | 0.91 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580850-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2013-11-12 | — | — | US | claimed |
| US-20130041026-A1 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE | XENOPORT, INC. (US) | 2013-02-14 | — | — | US | claimed |
| WO-2013023155-A1 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE | XENOPORT, INC. (US) | 2013-02-14 | — | — | WO | claimed |
| EP-1660440-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT INC (US) | 2012-02-22 | — | — | EP | claimed |
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | ARBOR PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | ARBOR PHARMACEUTICALS, LLC | 2018-09-13 | — | — | US | disclosed |
| US-9944592-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9353057-B2 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9265748-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265748-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-7300956-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070244331-A1 | Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof | XENOPORT, INC. | 2007-10-18 | — | — | US | disclosed |
| US-7227028-B2 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070054945-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070037988-A9 | Formation of a thiocarbamate from a haloformic compound, dehalo-esterification, coupling an N-hydroxysuccinimide or secondary amide-containing drug; prodrugs of gabapentin and baclofen; improved bioavailability | XENOPORT, INC. | 2007-02-15 | — | — | US | disclosed |
| US-7109239-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050222431-A1 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. | 2005-10-06 | — | — | US | disclosed |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | GABBR2 6/4885GABBR1 7/4885LMNA 3875/4885 |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | GABBR2 6/4885GABBR1 7/4885LMNA 3875/4885 |
| US-20130041026-A1 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE | GABRB3, GABRB1, GABBR1 | GABBR2 4/4885GABBR1 3/4885LMNA 3212/4885 |
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | GABBR2 6/4885GABBR1 7/4885LMNA 3875/4885 |
| US-20050222431-A1 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | CPS1, ACMSD, NAAA | GABBR2 1180/4885GABBR1 974/4885LMNA 3003/4885 |
| US-20070054945-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | GABBR2 6/4885GABBR1 7/4885LMNA 3875/4885 |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | GABBR2 6/4885GABBR1 7/4885LMNA 3875/4885 |
| US-20070244331-A1 | Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof | CPS1, ACMSD, NAAA | GABBR2 1180/4885GABBR1 974/4885LMNA 3003/4885 |
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | GABBR2, GABBR1, GABRB1 | GABBR2 1/4885GABBR1 2/4885LMNA 2604/4885 |
| US-20070037988-A9 | Formation of a thiocarbamate from a haloformic compound, dehalo-esterification, coupling an N-hydroxysuccinimide or secondary amide-containing drug; prodrugs of gabapentin and baclofen; improved bioavailability | SLC6A13, SLC6A11, SLC6A1 | GABBR2 11/4885GABBR1 4/4885LMNA 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.